Altria Group’s stock has returned 123.0% over the past 5 years, and both its intrinsic value estimate using a Discounted Cash Flow (DCF) approach and its market multiples currently point to the shares screening as undervalued. This leaves investors to assess how durable that apparent discount really is.
The issue now is whether Altria Group’s current share price around US$72.17 still offers a margin of safety relative to its intrinsic value estimate and earnings based multiples.
The Discounted Cash Flow (DCF) model estimates what Altria Group’s future cash flows might be worth in today’s dollars. Altria Group generated about $8.7b of free cash flow over the latest twelve months, and the DCF framework in this case assumes these cash flows keep growing rather than shrinking over time.
On that basis, the model points to an intrinsic value of about $132 per share, compared with the current share price around $72. Because the FDA’s proposal to tighten rules on foreign tobacco manufacturers could affect Altria Group’s cash generation, and the stock trades below this DCF estimate, the gap suggests the market is applying a sizable discount to those projected cash flows under the model’s assumptions.
Overall, the DCF workup indicates Altria Group stock appears undervalued relative to the cash flows implied in the model’s inputs and assumptions.
Our Discounted Cash Flow (DCF) analysis suggests Altria Group is undervalued by 45.5%. Track this in your watchlist or portfolio, or discover 47 more high quality undervalued stocks.
The P/E ratio is a useful yardstick for Altria Group because earnings remain a central focus for income oriented investors. Altria Group trades on a P/E of about 15.0x, which sits above the Tobacco industry average near 11.6x but below the broader peer group average of roughly 27.1x.
Simply Wall St’s fair P/E for Altria Group is around 20.2x, based on its mix of profitability, risk profile and sector characteristics. Compared with the current 15.0x, this suggests the stock trades at a discount to what that model indicates could be reasonable for the business, taking into account industry and peer benchmarks.
On this P/E yardstick, Altria Group stock appears undervalued relative to the earnings multiple implied by its fundamentals.
See what the numbers say about this price — find out in our valuation breakdown.
Simply Wall St Narratives pick up where Altria Group’s valuation puzzle leaves off by spelling out which assumptions on growth, margins and earnings would need to hold for the stock to be worth materially more or less than today’s price. Each narrative ties a fair value to a particular story about Altria Group’s potential catalysts and risks, so you can watch over time which version of events appears to be taking shape. They are hosted on Simply Wall St’s Community page.
One of the top community narratives on Altria Group: roughly fairly valued
"Even with higher fair value estimates, more cautious analysts, including those maintaining an Underweight stance, highlight that Altria Group still faces execution risk in converting regulatory clarity into profitable growth…"
Read one of the top narratives on Altria Group
Do you think there's more to the story for Altria Group? Head over to our Community to see what others are saying!
For Altria Group, both the Discounted Cash Flow (DCF) intrinsic value estimate and the earnings multiple workups currently point to the stock looking undervalued, rather than just one model flashing cheap on its own. With the broader valuation checks landing in a mixed tier, the current discount still needs to be weighed against ongoing regulatory shifts and the move away from traditional cigarettes. The key question for investors is whether Altria Group can continue to convert its regulatory position and product transition into resilient cash flows, or whether the present discount proves to be more of a value trap than an opportunity.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com